D Zhang, H Lee, Y Jin - RNA Interference and CRISPR Technologies …, 2020 - Springer
Extracellular vesicles (EVs) are naturally generated nanovesicles which potentially mediate the intercellular communication and interorgan crosstalk. EVs have recently gained …
D Zhang, H Lee, X Wang, A Rai, M Groot, Y Jin - Molecular Therapy, 2018 - cell.com
Exosomes (EXOs) are a type of extracellular nanovesicles released from living cells. Accumulating evidence suggests that EXOs are involved in the pathogenesis of human …
KD Popowski, A Moatti, G Scull, D Silkstone, H Lutz… - Matter, 2022 - cell.com
Respiratory diseases are a global burden, with millions of deaths attributed to pulmonary illnesses and dysfunctions. Therapeutics have been developed, but they present major …
L De Backer, T Naessens, S De Koker, E Zagato… - Journal of Controlled …, 2015 - Elsevier
The local delivery of small interfering RNA (siRNA) to the lungs may provide a therapeutic solution to a range of pulmonary disorders. Resident alveolar macrophages (rAM) in the …
Despite lipid nanoparticles'(LNPs) success in the effective and safe delivery of mRNA vaccines, an inhalation-based mRNA therapy for lung diseases remains challenging. LNPs …
J Chen, S Ma, B Luo, H Hao, Y Li, H Yang… - Journal of …, 2023 - Springer
Background Acute lung injury (ALI), manifested as strong pulmonary inflammation and alveolar epithelial damage, is a life-threatening disease with high morbidity and mortality …
Inhalation therapy with small interfering RNA (siRNA) is a promising approach in the treatment of pulmonary disorders. However, clinical translation is severely limited by the lack …
Although mRNA lipid nanoparticles (LNPs) are highly effective as vaccines, their efficacy for pulmonary delivery has not yet fully been established. A major barrier to this therapeutic …
Exposure to environmental tobacco smoke (ETS) is a known risk factor for the development of chronic lung diseases, cancer, and the exacerbation of viral infections. Extracellular …